SEC Form 4 · accession 0001810417-26-000016
Avalo Therapeutics, Inc. · AVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Ryan Sullivan
Officer — Chief Financial Officer
Period of report
Jun 10, 2026
Accepted (ET)
Jun 12, 2026 · 4:36 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001534120
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 10, 2026 | F | 138 | $13.10 | D | 40,773 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes 588 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction.